Anne Blackwood‐Chirchir

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

J. O’Shaughnessy, Lee S. Schwartzberg, Michael A. Danso et al. · Journal of Clinical Oncology · 2011 · 244 citations

Medicine, Oncology, Pharmacology +16

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

Lisa J. Christopher, Donghui Cui, Chi‐Yuan Wu et al. · Drug Metabolism and Disposition · 2008 · 197 citations

Medicine, Pharmacokinetics, Pharmacology +13

Silent infarcts in young children with sickle cell disease

Janet L. Kwiatkowski, Robert A. Zimmerman, Avrum N. Pollock et al. · British Journal of Haematology · 2009 · 185 citations · Full text

Medicine, Neurology, Pediatrics +11

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso et al. · Clinical Cancer Research · 2006 · 149 citations

Medicine, Pharmacokinetics, Pharmacology +13